Apatinib Plus Toripalimab (Anti-PD1 Therapy) as Second-Line Therapy in Patients With Advanced Gastric or Esophagogastric Junction Cancer: Results From a Randomized, Open-Label Phase II StudyQing Wei, Jieer Ying, Cong Luo et al.|The Oncologist|2024Cited by 10
Multi-omics analysis uncovers predictive biomarkers for the efficacy and outcomes of chemoimmunotherapy in advanced unresectable biliary tract cancersJiaojiao Ni, Jieer Ying, Chaoqun Li et al.|BMC Medicine|2025Cited by 7
Abstract 5132: Multi-omics analysis uncovers predictive biomarkers for the efficacy and outcomes of immune checkpoint inhibitor in combination with chemotherapy in advanced unresectable biliary tract cancersJieer Ying, Haimeng Tang, Qi Xu et al.|Cancer Research|2024Cited by 0